Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

3358 - Second-line metastatic urothelial carcinoma treatment and survival in real-world patients in the US


09 Oct 2016


Poster display


Sumanta Pal


Annals of Oncology (2016) 27 (6): 266-295. 10.1093/annonc/mdw373


S.K. Pal1, M.D. Galsky2, S. Lin3, S. Ogale3, M. Zivkovic4, J. Simpson3, C. Derleth3, G. Sonpavde5

Author affiliations

  • 1 Medical Oncology And Experimental Therapuetics, City of Hope, 91010 - Duarte/US
  • 2 Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York/US
  • 3 Health Economics & Outcomes Research, Genentech, Inc., South San Francisco/US
  • 4 Oncology, Genesis Research, Hoboken/US
  • 5 Medical Oncology, University of Alabama at Birmingham Hospital, 35294-3280 - Birmingham/US


Abstract 3358


Currently, there is no global standard of care for treatment of patients with metastatic urothelial cancer (mUC) who progress despite platinum-based chemotherapy. Practice guidelines recommend varied approaches from supportive care alone to single-agent chemotherapy based largely on the results of small single-arm trials that demonstrated modest activity. The treatment and outcomes of real-world patients with mUC treated with second-line (2L) systemic therapies remains underexplored.


Pts diagnosed with stage IV transitional cell carcinoma of the bladder from 1/2004 to 12/2011 were identified in the US SEER-Medicare database. Other criteria included ≥ 66 y of age at diagnosis (1 y after Medicare eligibility), with no prior cancer diagnosis and enrolled in Medicare Parts A and B. 2L chemotherapy regimens were defined as any change in 1L chemotherapy or start of new treatment upon completion of 1L. Kaplan-Meier methods were used to assess survival by 2L treatment approach (follow up through 12/2013).


240 mUC pts treated with 2L chemotherapy were included. Median age at diagnosis was 75 y (IQR 71-79 y), and 81% of pts were aged ≥ 70 y; 74% were male and 93% were white. Most pts (199/240, 83%) received cisplatin- or carboplatin-based prior 1L therapies. The most common comorbidities included diabetes (16%) and chronic obstructive pulmonary disease (10%). Among pts receiving 2L chemotherapy, 40% (97/240) received single agents. The majority of pts who received single-agents had taxanes (paclitaxel 37/97, 38%; docetaxel 20/97, 21%), followed by gemcitabine (19/97, 20%) and other single agents (21/97, 21%). The median overall survival (OS) in pts receiving any single-agent 2L chemotherapy was 6.4 mo (95% CI, 4.4,-8.5 mo), with a 24-mo OS rate of 13%. The median OS in pts receiving single-agent taxanes was 5.2 mo (95% CI, 3.5-8.6 mo), with a 24-mo OS rate of 8%.


In this real-world mUC population, pts received a wide variety of therapies in the 2L setting. Regardless of the treatment approach, outcomes were generally poor with a low likelihood of durable disease control. These results may serve as a benchmark for the effectiveness of novel therapies currently being developed for the treatment of mUC.

Clinical trial identification


Legal entity responsible for the study

F. Hoffmann-La Roche Ltd.


F. Hoffmann-La Roche Ltd.


M.D. Galsky: Advisory Board: Genentech, Merck, Astellas, Novartis, Consulting: BioMotiv. Research funding: Novartis, NMS, Celgene. S-W. Lin, S. Ogale, C. Derleth: Employee of Genentech, Inc. M. Zivkovic: Employee of Genesis Research. J. Simpson: Employee of Genentech, Inc. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings